

Personal Information



Nageshwara Arvind Dasari

Address: MD Anderson Cancer Center

Country: USA

Curriculum Vitae

PRESENT TITLE AND AFFILIATION

Primary Appointment

Assistant Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

N/A

CITIZENSHIP

India, U.S. Permanent Resident

OFFICE ADDRESS

The University of Texas MD Anderson Cancer Center
Department of Gastrointestinal Medical Oncology
1515 Holcombe Boulevard
Unit Number: 426
Houston, TX 77030
Room Number: FC10.2052
Phone: 713-792-2828

EDUCATION

Degree-Granting Education

NTR University of Health Sciences, Hyderabad, India, MBBS, 2002, Internal Medicine
University of Pittsburgh, Pittsburgh, PA, MS, 2005, Human Genetics

Postgraduate Training

Clinical Internship, Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, 2005-2006
Clinical Residency, Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, 2006-2008
Clinical Fellowship, Medical Oncology, University of Colorado at Denver, Aurora, CO, 2008-2011
Clinical Fellowship, Drug Development, University of Colorado at Denver, Aurora, CO, 2009-2011

CREDENTIALS

Board Certification

Andhra Pradesh State Medical License, 2005
Diplomate in Internal Medicine, 2008-2018
Diplomate in Medical Oncology, 2012-2022

Licensures

Active

Texas Medical Board, TX, P0718, 11/2011

Inactive

Colorado Physician Training License, CO, 0002679, 7/2008-8/2011

EXPERIENCE/SERVICE

Academic Appointments

Assistant Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 6/2011-present

Administrative Appointments/Responsibilities

N/A

Other Appointments/Responsibilities

Member, Gastrointestinal Cancers Committee, Southwest Oncology Group, Houston, TX, 2015-present

Endowed Positions

N/A

Consultantships

N/A

Military or Other Governmental Service

N/A

Institutional Committee Activities

Neuroendocrine Multidisciplinary Conference, Co-Chair, 2015-present
Physician Network Multidisciplinary Planning Conference, Faculty Member, 2015-present
Physician Network Multidisciplinary Planning - Queens Hospital, Member, 2015-present
Clinical Research Committee #1, Member, 9/2017-8/2018

HONORS AND AWARDS

Outstanding Academic Performance Award, University of Pittsburgh, 2006
31st Annual Honor Convocation, University of Pittsburgh, 2007
Best Senior Resident, University of Pittsburgh, 2008
AACR Workshop on Molecular Biology in Clinical Oncology, American Association of Cancer Research, 2011
Molecular and Translational Oncology Workshop, Cancer Education Consortium, 2011
AACR/ASCO Workshop on Methods in Clinical Cancer Research, American Association of Cancer Research & American Society of Clinical Oncology, 2012
Markers in Cancer Diagnostic Development Tutorial, 2012
2015 YI & NCIS Scholarship, NANETS

RESEARCH

Grants and Contracts

Funded

Principal Investigator, Multi-Center Chart Review Study in the US to Examine Treatment Patterns and Associated Outcomes Among Patients with Advanced Neuroendocrine Tumors (NET) of Gastrointestinal (GI) or Lung Origin, PA16-0575, Novartis, 1/1/2016-present
Principal Investigator-MDACC, 2015 NANET Clinical Investigator Scholarship, 2015 NANET Clinical Investigator Scholarship, MDACC

Pending

N/A

Other

N/A

Completed

N/A

Not Funded

N/A

Protocols

Funded

Principal Investigator, Phase III CLARINET Study Assessing the effect of Lanreotide autogel on tumor progression-free survival in patients with non-functioning gastroenteropancreatic neuroendocrine tumors, 2008-0483, 2008-present, MD Anderson Cancer Center

Principal Investigator, A Phase 1B of the combination of AZD6244 hydrogen sulfate (selumetinib) and cyclosporin A (CsA) in patients with advanced solid tumors with an expansion cohort in metastatic colorectal cancer, NCI 9571, 2014-present, MD Anderson Cancer Center

Principal Investigator, A Phase II study of LEE011 in patients with advanced neuroendocrine tumors of foregut origin, 2014-0371, 2015-present, Novartis

Principal Investigator, An open-label randomized Phase II study to assess the efficacy and safety of nintedanib alone or in combination with capecitabine for patients with refractory metastatic colorectal cancer, 2016-present, Boehringer Ingelheim

Principal Investigator, A Phase I study of TVEC with neoadjuvant chemoradiation in rectal cancer, NCI10058, 2017-present, NCI/CTEP

Principal Investigator, A Phase II study of lenvatinib in combination with everolimus in patients with advanced carcinoid tumors, 2017-present, Ipsen

Principal Investigator, A Phase II study of pembrolizumab in high grade neuroendocrine carcinomas, 2017-present, Merck

Principal Investigator, Living Life with Neuroendocrine Tumors: Assessing Quality of Life Through a Mobile Application, 2017-present, Ipsen

Unfunded

Principal Investigator, A Phase I study of everolimus in combination with theraspheres in patients with liver predominant neuroendocrine tumors, 2011-1205, 2011-present, BTG Interventional Medicine

Principal Investigator, A Phase II study of capecitabine in locally advanced rectal cancer with ziv-aflibercept, 2014-610, 2014-present, Sanofi

Patents and Technology Licenses

Patents

N/A

Technology Licenses

N/A

Grant Reviewer/Service on Study Sections

N/A

PUBLICATIONS

Peer-Reviewed Original Research Articles

1. **Dasari A**, Bartholomew JN, Volonte D, Galbiati F. Oxidative stress induces premature senescence by stimulating caveolin-1 gene transcription through p38 mitogen-activated protein kinase/Sp1-mediated activation of two GC-rich promoter elements. *Cancer Res* 66(22):10805-14, 11/2006. PMID: PMC4288740.
2. **Dasari A**, Yu ZZ, Mai YW, Kim JK. Orientation and the extent of exfoliation of clay on scratch damage in polyamide 6 nanocomposites. *Nanotechnology* 19(5):055708, 2/2008. e-Pub 1/2008. PMID: 21817622.
3. **Dasari A**, Yu ZZ, Mai YW, Yang M. The location and extent of exfoliation of clay on the fracture mechanisms in nylon 66-based ternary nanocomposites. *J Nanosci Nanotechnol* 8(4):1901-12, 4/2008. PMID: 18572592.
4. **Dasari A**, Messersmith WA. New strategies in colorectal cancer: biomarkers of response to epidermal growth factor receptor monoclonal antibodies and potential therapeutic targets in phosphoinositide 3-kinase and mitogen-activated protein kinase pathways. *Clin Cancer Res* 16(15):3811-8, 8/2010. e-Pub 6/2010. PMID: 20554751.
5. **Dasari A**, McCarter M, McManus MC, Russ P, Messersmith WA. Recurrent pancreatic adenocarcinoma after pancreatic resection. *Oncology (Williston Park)* 24(14):1329-34, 12/2010. PMID: 21294478.

6. Harry BL, Smith ML, Burton JR, **Dasari A**, Eckhardt SG, Diamond JR. Medullary thyroid cancer and pseudocirrhosis: case report and literature review. *Curr Oncol* 19(1):e36-41, 2/2012. PMID: PMC3267595.
7. Ma HL, Zhang HB, Hu QH, Li WJ, Jiang ZG, Yu ZZ, **Dasari A**. Functionalization and reduction of graphene oxide with p-phenylene diamine for electrically conductive and thermally stable polystyrene composites. *ACS Appl Mater Interfaces* 4(4):1948-53, 4/2012. e-Pub 3/2012. PMID: 22422027.
8. Arcaroli JJ, Quackenbush KS, Powell RW, Pitts TM, Spreafico A, Varella-Garcia M, Bemis L, Tan AC, Reinemann JM, Touban BM, **Dasari A**, Eckhardt SG, Messersmith WA. Common PIK3CA mutants and a novel 3'UTR mutation are associated with increased sensitivity to saracatinib. *Clin Cancer Res* 18(9):2704-14, 5/2012. PMID: PMC3836589.
9. Arcaroli JJ, Powell RW, Varella-Garcia M, McManus M, Tan AC, Quackenbush KS, Pitts TM, Gao D, Spreafico A, **Dasari A**, Touban BM, Messersmith WA. ALDH⁺ tumor-initiating cells that exhibit a gain in notch1 gene copy number have enhanced sensitivity to a γ -secretase inhibitor + irinotecan in colorectal cancer (CRC). *Mol Oncol* 6(3):370-81, 6/2012. e-Pub 3/2012. PMID: PMC4033713.
10. Tolcher AW, Messersmith WA, Mikulski SM, Papadopoulos KP, Kwak EL, Gibbon DG, Patnaik A, Falchook GS, **Dasari A**, Shapiro GI, Boylan JF, Xu ZX, Wang K, Koehler A, Song J, Middleton SA, Deutsch J, Demario M, Kurzrock R, Wheler JJ. Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors. *J Clin Oncol* 30(19):2348-53, 7/2012. e-Pub 4/2012. PMID: 22529266.
11. Arcaroli J, Quackenbush K, Dasari A, Powell R, McManus M, Tan AC, Foster NR, Picus J, Wright J, Nallapareddy S, Erlichman C, Hidalgo M, Messersmith WA. Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer. *Cancer Med* 1(2):207-17, 10/2012. e-Pub 8/2012. PMID: PMC3544442.
12. **Dasari A**, Gore L, Messersmith WA, Diab S, Jimeno A, Weekes CD, Lewis KD, Drabkin HA, Flaig TW, Camidge DR. A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer. *Invest New Drugs* 31(1):115-25, 2/2013. e-Pub 3/2012. PMID: 22415798.
13. Phua SL, Yang L, Toh CL, Guoqiang D, Lau SK, **Dasari A**, Lu X. Simultaneous enhancements of UV resistance and mechanical properties of polypropylene by incorporation of dopamine-modified clay. *ACS Appl Mater Interfaces* 5(4):1302-9, 2/2013. e-Pub 2/2013. PMID: 23360646.
14. Azad N, **Dasari A**, Arcaroli J, Taylor GE, Laheru DA, Carducci MA, McManus M, Quackenbush K, Wright JJ, Hidalgo M, Diaz LA, Donehower RC, Zhao M, Rudek MA, Messersmith WA. Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer. *Invest New Drugs* 31(2):345-54, 4/2013. e-Pub 5/2012. PMID: PMC3674958.
15. Rogers JE, Ohinata A, **Dasari A**, Eng C. Atypical metastatic presentations in colorectal cancer: a case series. *Clin Colorectal Cancer* 13(1):e1-4, 3/2014. e-Pub 11/2013. PMID: 24342822.
16. De Jesus-Acosta A, Laheru D, Maitra A, Arcaroli J, Rudek MA, **Dasari A**, Blatchford PJ, Quackenbush K, Messersmith W. A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma. *Invest New Drugs* 32(4):739-45, 8/2014. e-Pub 3/2014. PMID: PMC4292847.
17. Morris V, Overman MJ, Jiang ZQ, Garrett C, Agarwal S, Eng C, Kee B, Fogelman D, **Dasari A**, Wolff R, Maru D, Kopetz S. Progression-Free Survival Remains Poor Over Sequential Lines of Systemic Therapy in Patients With BRAF-Mutated Colorectal Cancer. *Clin Colorectal Cancer* 13(3):164-71, 9/2014. e-Pub 6/2014. PMID: PMC4266576.
18. **Dasari A**, Yao J. Initial treatment of well-differentiated neuroendocrine tumors. *Oncology (Williston Park)* 28(11):945-7, 11/2014. PMID: 25741544.

19. Messersmith WA, Shapiro GI, Cleary JM, Jimeno A, **Dasari A**, Huang B, Shaik MN, Cesari R, Zheng X, Reynolds JM, English PA, McLachlan KR, Kern KA, LoRusso PM. A phase I dosing finding study in patients with advanced solid malignancies of the oral γ -secretase inhibitor PF-03084014. *Clinical Cancer Res* 21(1):60-7, 1/2015. e-Pub 9/2014. PMID: 25231399.
20. Morelli MP, Overman MJ, **Dasari A**, Kazmi SM, Mazard T, Vilar E, Morris VK, Lee MS, Herron D, Eng C, Morris J, Kee BK, Janku F, Deaton FL, Garrett C, Maru D, Diehl F, Angenendt P, Kopetz S. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. *Ann Oncol* 26(4):731-6, 4/2015. e-Pub 1/2015. PMCID: PMC4374387.
21. **Dasari A**, Phan A, Gupta S, Rashid A, Yeung SC, Hess K, Chen H, Tarco E, Chen H, Wei C, Anh-Do K, Halperin D, Meric-Bernstam F, Yao J. Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and actreotide in advanced well differentiated neuroendocrine tumors. *Endocr Relat Cancer* 22(15):0002, 6/2015. e-Pub 4/2015. PMCID: PMC4566955.
22. Choi I, **Dasari A**, Kim NH, Campbell KH. Effects of prolonged exposure of mouse embryos to elevated temperatures on embryonic developmental competence. *Reprod Biomed Online* 31(2):171-9, 8/2015. e-Pub 5/2015. PMID: 26093856.
23. Halperin DM, **Dasari A**, Yao JC. [177Lu-DOTA0,Tyr3]-octreotate in the treatment of midgut neuroendocrine tumors. *Future Oncol* 12(3):313-21, 2/2016. e-Pub 1/2016. PMID: 26759064.
24. Rudek MA, **Dasari A**, Laheru D, Zhao M, He P, Walker R, Jimeno W, Purcell T, Donehower RC, Hidalgo M, Messersmith WA. Phase I study of ABT-751 in combination with CAPIRI (capecitabine and irinotecan) and bevacizumab in patients with advanced colorectal cancer. *Cancer Chemotherapy and Pharmacology* 56(8):966-73, 2016 Aug 2017. e-Pub 2/2016. PMID: 26632033.
25. Choi JS, **Dasari A**, Hu P, Benkovic SJ, Berdis AJ. The use of modified and non-natural nucleotides provide unique insights into pro-mutagenic replication catalyzed by polymerase ϵ . *Nucleic Acids Res* 44(3):1022-35, 2/2016. e-Pub 12/2015. PMCID: PMC4756837.
26. Shen C, Xu Y, **Dasari A**, Shih YC, Yao JC. Octreotide LAR Dosage and Survival Among Elderly Patients With Distant-Stage Neuroendocrine Tumors. *Oncologist* 21(3):308-13, 3/2016. e-Pub 2/2016. PMCID: PMC4786356.
27. Rogers JE, **Dasari A**, Eng C. The Treatment of Colorectal Cancer During Pregnancy: Cytotoxic Chemotherapy and Targeted Therapy Challenges. *Oncologist* 21(5):563-70, 5/2016. e-Pub 3/2016. PMCID: PMC4861360.
28. Mehrvarz Sarshekeh A, Halperin DM, **Dasari A**. Update on management of midgut neuroendocrine tumors. *Int J Endocr Oncol* 3(2):175-189, 5/2016. e-Pub 4/2016. PMCID: PMC4915384.
29. Conte B, George B, Overman M, Estrella J, Jiang ZQ, Mehrvarz Sarshekeh A, Ferrarotto R, Hoff PM, Rashid A, Yao JC, Kopetz S, **Dasari A**. High Grade Neuroendocrine Colorectal Carcinomas: A Retrospective Study of 100 Patients. *Clin Colorectal Cancer* 15(2):e1-7, 6/2016. e-Pub 12/2015. PMCID: PMC4885752.
30. Conte B, George B, Overman M, Estrella J, Jiang ZQ, Mehrvarz SA, Ferrarotto R, Hoff PM, Rashid A, Yao JC, Kopetz S, **Dasari A**. High-Grade Neuroendocrine Colorectal Carcinomas: A Retrospective Study of 100 Patients. *Clin Colorectal Cancer* 15(2):e1-7, 2016 June, 6/2016. e-Pub 12/2015. PMID: 26810202.
31. Overman MJ, Morris V, Kee B, Fogelman D, Xiao L, Eng C, **Dasari A**, Shroff R, Mazard T, Shaw K, Vilar E, Raghav K, Shureiqi I, Liang L, Mills GB, Wolff RA, Hamilton S, Meric-Bernstam F, Abbruzzese J, Morris J, Maru D, Kopetz S. Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials. *Ann Oncol* 27(6):1068-74, 6/2016. e-Pub 2/2016. PMID: 27045102.
32. Halperin DM, **Dasari A**, Yao JC. Future Directions in the Biology of Neuroendocrine Tumors. *Pancreas* 45(6):783-5, 7/2016. PMID: 27295529.
33. Rudek MA, **Dasari A**, Laheru D, He P, Jin R, Walker R, Taylor GE, Jimeno A, Donehower RC, Hidalgo M, Messersmith WA, Purcell WT. Phase 1 Study of ABT-751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced

- Colorectal Cancer. *J Clin Pharmacol* 56(8):966-73, 8/2016. e-Pub 2/2016. PMCID: PMC4892995.
34. Prakash L, Bhosale P, Cloyd J, Kim M, Parker N, Yao J, **Dasari A**, Halperin D, Aloia T, Lee JE, Vauthey JN, Fleming JB, Katz MH. Role of Fluorouracil, Doxorubicin, and Streptozocin Therapy in the Preoperative Treatment of Localized Pancreatic Neuroendocrine Tumors. *J Gastrointest Surg* 21(1):155-163, 2017 Jan. e-Pub 9/2016. PMID: 27634306.
 35. Conrad C, Kutlu OC, **Dasari A**, Chan JA, Vauthey JN, Adams DB, Kim M, Fleming JB, Katz MH, Lee JE. Prognostic Value of Lymph Node Status and Extent of Lymphadenectomy in Pancreatic Neuroendocrine Tumors Confined To and Extending Beyond the Pancreas. *J Gastrointest Surg* 20(12):1966-1974, 12/2016. e-Pub 10/2016. PMID: 27714644.
 36. Roland CL, Starker LF, Kang Y, Chatterjee D, Estrella J, Rashid A, Katz MH, Aloia TA, Lee JE, **Dasari A**, Yao JC, Fleming JB. Loss of DPC4/SMAD4 expression in primary gastrointestinal neuroendocrine tumors is associated with cancer-related death after resection. *Surgery* 161(3):753-759, 2017 Mar, 3/2017. PMID: 27816207.
 37. Halperin DM, Shen C, **Dasari A**, Xu Y, Chu Y, Zhou S, Shih YT, Yao JC. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. *Lancet Oncol* 18(4):525-534, 4/2017. e-Pub 2/2017. PMID: 28238592.
 38. **Dasari A**, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients with Neuroendocrine Tumors in the United States. *JAMA Oncol*. e-Pub 4/2017. PMID: 28448665.
 39. Sarshekeh AM, Advani S, Overman MJ, Manyam G, Kee BK, Fogelman DR, **Dasari A**, Raghav K, Vilar E, Manuel S, Shureiqi I, Wolff RA, Patel KP, Luthra R, Shaw K, Eng C, Maru DM, Routbort MJ, Meric-Bernstam F, Kopetz S. Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. *PLoS One* 12(5):e0173345, 2017 May 17, 5/2017. e-Pub 3/2017. PMID: 28267766.
 40. Hassan SA, Banchs J, Iliescu C, **Dasari A**, Lopez-Mattei J, Yusuf SW. Carcinoid Heart Disease. *Heart*. e-Pub 6/2017. PMID: 28596203.
 41. Shen C, Chu Y, Halperin DM, **Dasari A**, Zhou S, Xu Y, Yao JC, Shih YT. Carcinoid Syndrome and Costs of Care During the First Year After Diagnosis of Neuroendocrine Tumors Among Elderly Patients. *Oncologist*. e-Pub 6/2017. PMID: 28642335.
 42. Korphaisarn K, Morris VK, Overman MJ, Fogelman DR, Kee BK, Raghav KPS, Manuel S, Shureiqi I, Wolff RA, Eng C, Menter D, Hamilton SR, Kopetz S, **Dasari A**. FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. *Oncotarget* 8(24):39268-39279, 2017 Jun 13, 6/2017. PMID: 28424412.
 43. Parseghian CM, Parikh NU, Wu JY, Jiang ZQ, Henderson L, Tian F, Pastor B, Ychou M, Raghav K, **Dasari A**, Fogelman DR, Katsiampoura AD, Menter DG, Wolff RA, Eng C, Overman MJ, Thierry AR, Gallick GE, Kopetz S. Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. *Clin Cancer Res* 23(15):4146-4154, 2017 Aug 1, 8/2017. PMID: 28280091.

Invited Articles

1. **Dasari A** and Messersmith WA. Are additional clinical trials of adjuvant Bevacizumab therapy indicated in colon cancer? *Current Colorectal Cancer Reports* 7(3), 2011.
2. Arcaroli JJ, **Dasari A**, Messersmith WA, Jimeno A. Gamma secretase inhibitors in solid tumor malignancies. *Drugs of the Future* 36(9):677, 2011.
3. Harry BL, Smith ML, Burton JR Jr, **Dasari A**, Eckhardt SG, Diamond JR. Medullary thyroid cancer and pseudocirrhosis: case report and literature reviews. *Curr Oncol* 19(1):e36-41, 2012.
4. **Dasari A**, Yao J. Initial treatment of well differentiated neuroendocrine tumors. *Oncology* 28(11):945-7, 2014/Nov, 11/2014.

Editorials

1. **Dasari A**, Yao JC. Gastrointestinal neuroendocrine tumors: slow but steady progress. *Oncology* 28(9):762-3, 9/2014, 9/2014. PMID: 25224473.
2. **Dasari A**, Yao JC. Gastrointestinal neuroendocrine tumors: slow but steady progress. *Oncology (Williston Park)* 28(9):762-3, 9/2014. PMID: 25224473.

Other Articles

N/A

Abstracts

1. **Dasari A**, S Malhoirta., CL Spanoletti. A rare complication of a common disease: Pyogenic liver abscess due to diverticulitis. SGIM Meeting 2008 Annual Meeting Proceedings JGIM 23(2):89-443, 1/2008.
2. Malthra S, A Lertratanakul., **Dasari A**, CL Spagnoletti. An unusual cause for low back pain: Mycotic abdominal aneurysm. SGIM Meeting 2008 Annual Meeting Proceedings JGIM 23(2):89-443, 2008.
3. **Dasari A**, S Malhotra., CL spagnoletti. Sore Throat - Not always the usual suspect. SGIM Meeting 2008 Annual Meeting Proceedings JGIM 23(2):89-443, 2008.
4. **Dasari A**, Gore L, Messersmith AW, Diab S, Jimeno A, Weekes CD, Lewis KD, Drabkin HA, Flaig TW, Camidge DR. A Phase I Safety and Tolerability Study of Vorinostat (V) in Combination with Sorafenib (S) in Patients With Advanced Solid tumors, With Exploration of Two Tumor-Type Specific Expanded Cohorts at the Recommended Phase II Dose (Renal and Non-Small Cell Lung Carcinoma). ASCO Annual Meeting 2010 (#2562), 2010.
5. Powell RW, Messersmith W, Garcia M, Tan AC, Touban B, Pitts T, **Dasari A**. The combination of PF03084014 (a γ -secretase inhibitor) and Irinotecan reduces ALDH+ tumor-initiating cells and recurrence in tumors with elevated notch pathway. AACR 2010, 2010.
6. Powell RW, Tan AC, Varella-Gacia M, Touban B, **Dasari A**, Puls L, Pitts L, Kulikowski G, Quackenbush K, Messersmith W, Arcaroli JJ. Biomarkers for sensitivity to gamma secretase inhibitors in mouse models of pancreatic adenocarcinoma. (#5190), 4/2011.
7. Messersmith WA, LoRusso P, Cleary JM, **Dasari A**, Zhang X, Shaik MN, Courtney RD, Randoulph S, Shapiro G. A Phase I dose-escalation study of the novel gamma secretase inhibitor PF-03084014 in patients (pts) w ith advanced solid tumors. ASCO 2011 Annual Meeting 29(15):3100, 2011.
8. **Dasari A**, MA Rudek, J Arcaroli., RW Powell, MA Carducci, D Laheru, JJ Wright, M Hidalgo, WA Messersmith. Tolerance of full-dose sorafenib (S) combined with irinotecan (i;weekly, two on one off) and cetuximab (C) in previously treated patients with advanced colorectal cancer (CRC). 2011 ASCO Meeting 29(4):522, 2011.
9. **Dasari A**, Gao H, Deaton L, Overman MJ, Hauch S, Kopetz S, Reuben JM. Association of mesenchymal phenotype in circulating tumor cells with poor prognosis in metastatic colorectal cancer. ASCO 2013 Annual Meetings, J Clin Oncol 31 (#e14567), 6/2013.
10. Morelli MP, Overman MJ, **Dasari A**, Kazmi SMA, Vilar Sanchez E, Eng C, Kee BK, Deaton L, Garrett CR, Diehl F, Angenendt P, Kopetz S. Heterogeneity of acquired KRAS and EGFR mutations in colorectal cancer patients treated with anti-EGFR monoclonal antibodies. ASCO 2013 Meetings, J Clin Oncol 31 (#3512), 2013.
11. **Dasari A**, Phan A, Gupta S, Hess KR, Culotta KS, Rashid A, Yeung SJ, Chen HX, Dong M, Halperin DM, Subbiah IM, Meric-Bernstam F Yao JC. A phase I study of the anti-IGF-1R monoclonal antibody (MoAb), IMC-A12 (I), and everolimus (E) in well differentiated neuroendocrine tumors (WD NET). 2014 ASCO Annual Meeting 32(3):232, 2014.
12. Hesham M. Hassabo, Ibrahim Halil Sahin, Syed Mohammad Ali Kazmi, Salwan S. Al Mutar, Diogo Bugano Diniz Gomes, Tunghi May Pini, Eduardo Vilar Sanchez, **Dasari A**, Scott Kopetz, Michael J. Overman, Cathy Eng, Bryan K Kee, Jean-Nicolas Vauthey, Manal Hassan, Chris R. Garrett. Associations between patient (pt) colorectal cancer (CRC) tumor KRAS and BRAF mutation (mut) status and overall survival (OS). 2014 Gastrointestinal cancer Symposium 32 (#473), 2014.
13. Conte B, George B, **Dasari A**, Overman MJ, Estrella J, Jiang Z, Machado K, Mello CL, Ferrarotto R, Hoff PM, Yao JC, Rashid A, Kopetz S. Colorectal high grade neuroendocrine carcinoma: a single institution experience. ASCO Annual Meeting 32(2):540, 2014.
14. Morris VK, Overman MJ, Kee BK, Fogelman DR, Eng C, **Dasari A**, Shroff RT, Deaton K, Manuel S, Garrett CR, Vilar Sanchez E, Pini TM, Shureiqi I, Mills GB, Hamilton SR, Wolff RA, Meric-Bernstam F, Abbruzzese JL, Maru DM, Kopetz S. Efficiency of biomarker

- screening for enriched metastatic colorectal cancer trials: The ATTACC program experience. 2014 Gastrointestinal Cancers Symposium 32 (#450), 2014.
15. Morris VK, Overman MJ, Kee BK, Fogelman DR, Eng C, **Dasari A**, Shroff RT, Deaton, Manuel L, Garrett CR, Sanchez V, Pini E, Shureiqi TM, Mills GB, Hamilton SR, Wolff RA, Meric-Bernstam F, Abbruzzese JL, Maru DM, Kopetz S. Efficiency of biomarkers screening for enriched metastatic colorectal cancer trials: The ATTACC program experience. GI ASCO Meeting 32(3):540, 2014.
 16. Bugano Diniz Gomes D, Hassabo HM, Al Mutar SS, Sahin IH, Rogers J, Nguyen DV, Bolonesi RM, Pini TM, **Dasari A**, Kopetz S, Overman MJ, Eng C, Kee BK, Hassan M, Garrett CR. MD Anderson experience with off study regorafenib in patients with advanced colorectal cancer. ASCO Annual Meeting 32(3):635, 2014.
 17. Kopetz S, Overman MJ, Chen K, Lucio-Eterovic AK, Kee BK, Fogelman DR, **Dasari A**, Raghav KPS, Vilar Sanchez E, Phillips J, Shureiqi I, Garrett CR, Wolff RA, Patel K, Aldape KD, Luthra R, Routbort M, Maru DM, Meric-Bernstam F, Eng C. Mutation and copy number discordance in primary versus metastatic colorectal cancer (mCRC). 2014 ASCO Annual Meeting 32:5s (#3509), 2014.
 18. Overman MJ, Kee BK, Fogelman DR, Eng C, Vilar Sanchez E, Shroff RT, **Dasari A**, Wolff RA, Morris J, Kopetz S. A phase II study of nab-paclitaxel in refractory CIMP-high metastatic colorectal cancer. J Clin Oncol 33 (#e14700), 2015.
 19. **Dasari A**. Lanreotide depot/autogel (LAN) in midgut neuroendocrine tumors (NETs): A subgroup analysis from the CLARINET study. 2015 ASCO Annual Meeting (#4104), 2015.
 20. Raj N, Chan J, **Dasari A**, Capanu M, Tang L, Reidy-Lagunes D. A Phase II Trial of LEE011 in Combination with Everolimus in the Treatment of Advanced Well Differentiated Neuroendocrine Tumors of Foregut Origin. NANETS 2016, October 2016, 10/2016.
 21. **Dasari A**, Mehta K, Byers L, Sorbye H, Yao J. Comparative Study of Pulmonary and Extrapulmonary High Grade Neuroendocrine Carcinomas: A SEER Database Analysis of 210195 Cases. NANETS 2016, 10/2016.
 22. Mehrvarz S, Advani S, Patel M, **Dasari A**. Prognostic validity of AJCC staging system in neuroendocrine tumors of the appendix. ESMO 2016, 10/2016.
 23. **Dasari A**, Shen C, Halperin D, Zhou S, Xu Y, Chu Y, Shih T, Yao J. Survival Trends in Neuroendocrine Tumors and Associated Prognostic Factors. NANETS 2016, 10/2016.
 24. **Dasari A**, Michael J. Overman, David R. Fogelman, Bryan K. Kee, David Menter, Kanwal Pratap Singh Raghav, Van Karlyle Morris, Jisu Oh, Ji Wu, Zhiqin Jiang, Feng Tian, Liana Adam, Mary Brimer, Jeffrey Morris, Funda Meric-Bernstam, Scott Kopetz. A phase II and co-clinical study of an AKT inhibitor in patients (pts) with biomarker-enriched, previously treated metastatic colorectal cancer (mCRC). 34 (#3563), 2016.
 25. Korphaisarn K, Overman MJ, Fogelman DR, Kee BK, Raghav KPS, Shureiqi I, Wolff RA, Patel K, Shaw KR, Eng C, Maru DM, Routbort M, Meric-Bernstam F, Kopetz S, Morris VK, Vilar-Sanchez E, Manuel S, **Dasari A**,. Association of FBXW7 missense mutations (mt) with unfavorable prognosis in metastatic colorectal cancer (mCRC) patients (pts). 2016 ASCO Annual Meeting 34 (#3607), 2016.
 26. **Dasari A**, Daniel M. Halperin, Shouhao Zhou, Yiyi Chu, Ying Xu, Tina Shih, James C. Yao, Chan Shen. Clinicopathological and demographic factors associated with development of distant metastasis among patients with locoregional neuroendocrine tumor (NET). J Clin Oncol 34 (#4099), 2016.
 27. Amir Mehrvarz Sarshekeh, Michael J. Overman, Bryan K. Kee, David R. Fogelman, **Dasari A**, Kanwal Pratap Singh Raghav, Eduardo Vilar Sanchez, Shanequa Manuel, Imad Shureiqi, Robert A. Wolff, Keyur Patel, Rajyalakshmi Luthra, Kenna Rael Shaw, Cathy Eng, Dipen M. Maru, Mark Routbort, Funda Meric-Bernstam, Scott Kopetz. Demographic, tumor characteristics, and outcomes associated with SMAD4 mutation in colorectal cancer. 2016 Gastrointestinal Cancer Symposium 34 (#565), 2016.
 28. Chan Shen, **Dasari A**, Shouhao Zhou, Yiyi Chu, Ying Xu, Ya-Chen T. Shih, James C. Yao, Daniel M. Halperin. Functional status of neuroendocrine tumors among elderly patients: A

large population-based study using SEER-Medicare data. 2016 ASCO Annual Meeting 34 (#4097), 2016.

29. Alexandria T. Phan, **Dasari A**, Nilani Liyanage, David Cox, Susan Pitman Lowenthal, Edward M. Wolin. Tumor response in the CLARINET study of lanreotide depot vs. placebo in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). 2016 Gastrointestinal Cancer Symposium 34 (#434), 2016.
30. Krishnamurthy A, **Dasari A**, Noonan AM, Mehnert JM, Lockhart AC, Stein MN, Sanoff HK, Lee JJ, Hansen AR, Malhotra U, Rippke S, Davis SL, Messersmith WA, Eckhardt SG, Lieu CH. A phase IB study of the combination of selumetinib (AZD6244, ARRY-142886) and cyclosporin A (CsA) in patients with advanced solid tumors with an expansion cohort in metastatic colorectal cancer (mCRC). J Clin Oncol (#2587), 6/2017.
31. Chun YS, Mehran RJ, Tzeng CD, Kee BK, **Dasari NA**, Sepsesi B, Conrad C, Aloia TA, Kopetz S, Vauthey JN. LUNA: A randomized phase II trial of liver resection plus chemotherapy or chemotherapy alone in patients with unresectable lung and resectable liver metastases from colorectal adenocarcinoma. J Clin Oncol (#TPS3625), 6/2017.
32. Shen C, Chu Y, **Dasari A**, Zhou S, Halperin DM, Xu Y, Shih YT, Yao JC. Pre-existing symptoms, resource utilization, and healthcare costs prior to diagnosis of neuroendocrine tumors: A SEER-Medicare database study. J Clin Oncol (#4092), 6/2017.
33. **Dasari A**, Shen C, Chu Y, Halperin DM, Xu Y, Zhou S, Shih T, Yao JC. Prevalence of comorbidities in elderly patients with distant stage neuroendocrine tumors. J Clin Oncol (#e15699), 6/2017.

Book Chapters

1. **Dasari A**, Messersmith WA. Colorectal Cancer. In: Clinical Decision Support System on Oncology, 2008.
2. **Dasari A**, Das P. Could upfront chemotherapy substitute preoperative radiochemotherapy? In: Multidisciplinary Management of Rectal Cancer - Questions and Answers, 2014.
3. **Dasari A**, Yao JC. Pancreatic neuroendocrine tumors. In: Textbook of Surgical Oncology. McGraw-Hill, 2014.

Books (edited and written)

N/A

Letters to the Editor

N/A

Manuals, Teaching Aids, Other Teaching Publications

N/A

Other Publications

N/A

EDITORIAL AND REVIEW ACTIVITIES

Editor/Service on Editorial Board(s)

N/A

Member of Editorial Review Board

N/A

Journal Reviewer

Reviewer, Journal of the National Comprehensive Cancer Network, 2013-2014

Reviewer, Annals of Oncology, 2013

Reviewer, Medical Oncology, 2013

Reviewer, Pharmacogenomics, 2013

Reviewer, Annals of Surgical Oncology, 2013-present

Reviewer, Clinical Cancer Research, 2013-present

Reviewer, Expert Opinion on Pharmacotherapy, 2014

Reviewer, Journal of Urology and Research, 2014

Reviewer, Lung Cancer, 2014

Reviewer, Oncotargets and Therapy, 2014

Reviewer, Personalized Medicine, 2014

Reviewer, Cancer Epidemiology Biomarker and Prevention, 2015

Reviewer, The Oncologist, 2015

Reviewer, Histology and Pathology, 2015-present

Other Editorial and Review Activities

Reviewer, Education Document on Appendix Cancers, Phyllis Pittman Communications Ltd, 2014

TEACHING

Teaching Within Current Institution - The University of Texas MD Anderson Cancer Center

Formal Teaching

Courses Taught

Teaching Faculty, CBP "The Biology of Cancer Metastasis"

Winter, 8/2016-12/2016

Instructor, GSBS CBP 2015 Fall Graduate Student Cancer Metastasis course

Training Programs

N/A

Other Formal Teaching

Faculty, Audio Digest Foundation Oncology Board Review: Neuroendocrine Carcinomas 2015

Supervisory Teaching

Committees

Advisory Committees

N/A

Supervisory Committees

N/A

Examining Committees

N/A

Direct Supervision

Undergraduate and Allied Health Students

N/A

Medical Students

N/A

Graduate Students

N/A

Postdoctoral Research Fellows

Direct Supervision, Medical Oncology Fellow, Continuity Clinic, John Frence MD, 6/2014-12/2015

Direct Supervision, Medical Oncology Fellow, Continuity Clinic, UT MD Anderson Cancer Center, Maryam Nemati Shafaei, 12/2015-3/2016

Direct Supervision, Medical Oncology Fellow, Continuity Clinic, UT MD Anderson Cancer Center, Christine Parseghian, 1/2016-6/2016

Clinical Residents and Fellows

N/A

Other Supervisory Teaching

N/A

Teaching Outside Current Institution

Formal Teaching

Courses Taught

N/A

Training Programs

N/A

Other Formal Teaching

N/A

Supervisory Teaching

Committees

Advisory Committees

N/A

Supervisory Committees

N/A

Examining Committees

N/A

Direct Supervision

Undergraduate and Allied Health Students

N/A

Medical Students

N/A

Graduate Students

N/A

Postdoctoral Research Fellows

N/A

Clinical Residents and Fellows

Mentor, University of Pittsburg, University of Pittsburgh, Kathan Mehta MD, MD, 2015

Other Supervisory Teaching

N/A

CONFERENCES AND SYMPOSIA

Organization of Conferences/Symposia (Include chairing session)

North American Neuroendocrine Tumor Society, Organizing & Education Committees, Member, 2014

Best of ASCO Panama 2014, Panamanian Society of Panama, Panama City, Panama, Session Chair, 7/2014

North American Neuroendocrine Tumor Society, Ispen, Guebert Group, Novartis, Pfizer, Chair, 2016

Presentations at National or International Conferences

Invited

ASCO, EORTC and NCI Markers in Cancer, ASCO, EORTC and NCI, Hollywood, FL, 10/10/2012

Dasari A. Colon Cancer, Best of ASCO Ecuador 2013, ASCO, Manta, Ecuador, 7/25/2013

SWOG Group Meeting, SWOG, Southwest Oncology Group, San Francisco, CA, 5/1/2014

Faculty Member - Best of ASCO Panama, Panamanian Society of Oncology, ASCO, Panama City, Panama, 7/24/2014

Panel Member: Complicated Case Presentations - Unknown Primary & Pancreatic NETs: The Cutting Edge in 2014, NANETS, North American Neuroendocrine Tumor Society, Nashville, TN, 10/11/2014

Other, Including Scientific Exhibitions

AACR/ASCO Workshp-Methods in Clinical Cancer Research, AACR/ASCO, Vail, CO, 7/28/2012

SWOG Board of Governors Fall Meeting, SWOG, SOUTHWEST ONCOLOGY GROUP, San Francisco, CA, 5/1/2013

Molecular Targets and Cancer Therapeutics Conference, ASCO, EORTC and NCI Webinar, Boston, MA, 10/19/2013

GI ASCO, ASCO, American Society of Clinical Oncology, San Francisco, CA, 1/16/2014

Dasari A. SWOG Group Meeting, SWOG, SOUTHWEST ONCOLOGY GROUP, San Francisco, CA, 5/1/2014

Dasari A. Adjuvant strategies in stage II-III colon cancer: Medical Education Program on CRC, GI Multidisciplinary Cancer Managemnt, UT MD Anderson Cancer Center, Houston, TX, 11/2015

Dasari, A. Complicated Case Presentation, Carcinoid Syndrome NANETS Annual Symposium, NANETS, Denver, CO, 2016

Seminar Invitations from Other Institutions

Coloan Cancer, Clinical Research Education Day, Aware for All, Houston, TX, 5/9/2014
 Advanced CRC, SUMO 2014 Fall Meeting, Society of Utah Medical Oncologists (SUMO), Park City, UT, 9/26/2014
 Gastric Cancer, SUMO 2014 Fall Meeting, Society of Utah Medical Oncologist, Park City, UT, 9/26/2014
 Management of Metastatic Colon Cancers, St Vincent's Medical Center, Bridgeport, CT, 11/15/2014
 Management of Well Differentiated Neuroendocrine Tumors, GI Oncology Symposium, Gi Medical Oncology, Tyler, TX, 6/13/2015
 mCRC, HCC and Gastric Cancer, oncoMAP Houston 2016, Methodist Institute for Technology Innovation and Education, Houston, TX, 11/2016

Lectureships and Visiting Professorships

Neuroendocrine Nets, New Frontiers and Critical Advances in Multimodal Management of Gastrointestinal Neuroendocrine Tumors (NETs), CMEducation Resources, LLC, Washington DC, WA, 4/23/2016
 Neuroendocrine Tumors (NETs), New Frontiers and Critical Advances in Multimodal Management of Gastrointestinal Neuroendocrine Tumors (NETs), CMEducation Resources, LLC, Chicago, IL, 5/7/2016
 Epidemiology and Classification of gastrointestinal Neuroendocrine Tumors (NETs): Translating Disease Type and Profiles into Meaningful Clinical Decision-Making., New Frontiers and Critical Advances in Multimodal Management of Gastrointestinal Neuroendocrine Tumors (NETs), CMEducation Resources, LLC, Philadelphia, PA, 5/14/2016
 Neuroendocrine Tumors, New Frontiers and Critical Advances in Multimodal Management of Gastrointestinal Neuroendocrine Tumors (NETs), CMEducation Resources, LLC, Seattle, WA, 6/18/2016

Other Presentations at State and Local Conferences

Dasari A. Post ASCO Update, Multidisciplinary Colorectal Cancer Clinical Translational Research Conference, University of Texas MD Anderson Cancer Center, GI Medical Oncology, Houston, TX, 6/25/2012
Dasari A. Colorectal Cancer: Prevention, Detection and Latest Treatments, 24th annual Cancer Survivorship Conference, Omni Westside Hotel, University of Texas MD Anderson Cancer Center, Volunteer Services-Anderson Network, Houston, TX, 9/14/2012
 New Developments in Colorectal Cancer Treatment, 2nd annual Physician Relations' Conference: Medical Oncology and Hematology 2012: Clinical and Scientific Approaches that Enhance Patient Outcomes, MDACC Physician Relations, Houston, TX, 10/19/2012
Dasari A. Adjuvant Therapy of Colorectal Cancer, Multidisciplinary Mgmt of the Oncological Patient, MDACC-Office of Global Academic Programs, Houston, TX, 3/22/2013
Dasari A. Colorectal cancer: Prevention, detection and latest treatment., Anderson Network - Ask the Expert 2013, The University of Texas MD Anderson Cancer Center, Houston, TX, 6/3/2013
 Dasari A. Adjuvant Therapy of Colon Cancer (Past, Present and Future), MDACC-Physician Relations Grand Rounds, Houston, TX, 3/26/2014
 Dasari A. Adjuvant strategies in stage II-III colon cancer., Medical Education Program on CRC - GI Multidisciplinary Cancer Management, UT MD Anderson Cancer Center, UT MD Anderson Cancer Center-Office of Global Academic Programs, Houston, TX, 11/6/2014
 Dasari A. Clinical implications of biomarkers in stage II-III colorectal cancer: Prognostic and Predictive assessment., Medical Education Program on CRC - GI Multidisciplinary Cancer Management, UT MD Anderson Cancer Center, UT MD Anderson Cancer Center-Office of Global Academic Programs, Houston, TX, 11/6/2014
 Tumor board: Stage II and III - Case Discussions Coordinator, Medical Education Program on CRC - GI Multidisciplinary Cancer Management, UT MD Anderson Cancer Center, UT MD Anderson-Office of Global Academic Programs, Houston, TX, 11/6/2014



13th International Conference of the
Asian Clinical Oncology Society
23-25 February 2018, Chiang Mai, Thailand

A Dasari. Update on Management of Colon Cancer, 11th Physicians Network Symposium: Translating Molecular Biology into Individualized Cancer Care, MD Anderson Cancer Center and Physicians Network Symposium, Houston, TX, 7/25/2015

A Dasari. Update on Management of Neuroendocrine Tumors, 1st Annual Tyler Gastrointestinal Oncology Symposium, East Texas Medical Center, Continuing Medical Education, Tyler, TX, 8/14/2015

A Dasari. Controversies in Timing of Therapy and Selection of Initial Therapy for Gastrointestinal Neuroendocrine Tumors (NETs): Critical Issues for Treatment Initiation and Subsequent Management of the Complex Patient, New Frontiers and Critical Advances in Multimodal management of Gastrointestinal Neuroendocrine Tumors., CMEducation Resources, LLC, Philadelphia, PA, 5/14/2016

A Dasaari. Epidemiology and classification of Gastrointestinal Neuroendocrine Tumors (NETs): Translating Disease Type and Profiles into meaningful Clinical Decision Making., New Frontier and Critical Advances in Multimodal Management of Gastrointestinal Neuroendocrine Tumors, CMEducation Resources LLC, Philadelphia, PA, 5/14/2016

New Therapeutic Options for Neuroendocrine Tumors, Novel and Exciting Advances in Cancer Therapeutics and Future Prospects, MD Anderson Physicians Network, Department of CME / Conference Management, Houston, TX, 10/21/2017

PROFESSIONAL MEMBERSHIPS/ACTIVITIES

Professional Society Activities, with Offices Held

National and International

American Medical Association

Member, 2005-present

American Society of Clinical Oncology

Member, 2008-present

American Association for Cancer Research

Member, 2009-present

American College of Physicians

Member, 2010-present

North American Neuroendocrine Tumor Society

Member, 2013-present

North American Neuroendocrine Tumor Society (NANETS)

Organizing Committee Member, 2013-present

Southwest Oncology Group (SWOG)

Group Member, 3/2013-present

Local/State

Rocky Mountain Oncology Society, Colorado

Member, 2008-2011

Texas Medical Society

Member, 11/2011-present

UNIQUE ACTIVITIES

N/A

DATE OF LAST CV UPDATE

9/25/2017